Debiopharm International SA: BIG IMPACT, SMALL PACKAGE: DEBIOPHARM LAUNCHES A WAZOKU OPEN-INNOVATION CHALLENGE FOR SMALL ANTIBODY DRUG CONJUGATE TECHNOLOGY
Currently approved Antibody-Drug Conjugates (ADCs) are large molecules (150 kDa) composed of an antibody, a cytotoxic payload, and a linker connecting the two precedent elementsDebiopharm has
Source: finanznachrichten.de
